168 related articles for article (PubMed ID: 22032416)
1. Pharmacokinetic evaluation of olopatadine for the treatment of allergic rhinitis and conjunctivitis.
Nickels AS; Dimov V; Wolf R
Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1593-9. PubMed ID: 22032416
[TBL] [Abstract][Full Text] [Related]
2. Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis.
Gonzalez-Estrada A; Reddy K; Dimov V; Eidelman F
Expert Opin Pharmacother; 2017 Aug; 18(11):1137-1143. PubMed ID: 28656804
[TBL] [Abstract][Full Text] [Related]
3. Azelastine and olopatadine in the treatment of allergic rhinitis.
Kaliner MA
Ann Allergy Asthma Immunol; 2009 Nov; 103(5):373-80. PubMed ID: 19927534
[TBL] [Abstract][Full Text] [Related]
4. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis.
Rosenwasser LJ; Mahr T; Abelson MB; Gomes PJ; Kennedy K
Allergy Asthma Proc; 2008; 29(6):644-53. PubMed ID: 19063816
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
Greiner JV; Udell IJ
Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
[TBL] [Abstract][Full Text] [Related]
6. Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug.
Ohmori K; Hasegawa K; Tamura T; Miyake K; Matsubara M; Masaki S; Karasawa A; Urayama N; Horikoshi K; Kajita J; Hasegawa M; Taniguchi K; Komada T; Kawamoto Y
Arzneimittelforschung; 2004; 54(12):809-29. PubMed ID: 15646365
[TBL] [Abstract][Full Text] [Related]
7. Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy.
Berger W; Abelson MB; Gomes PJ; Beck M; Kimura S; Westbrook T; Storms W; Galant S
Ann Allergy Asthma Immunol; 2005 Oct; 95(4):361-71. PubMed ID: 16279567
[TBL] [Abstract][Full Text] [Related]
8. Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older.
Roland PS; Ryan MW; Wall GM
Expert Opin Pharmacother; 2010 Jun; 11(9):1559-67. PubMed ID: 20482305
[TBL] [Abstract][Full Text] [Related]
9. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults.
Shah SR; Nayak A; Ratner P; Roland P; Michael Wall G
Clin Ther; 2009 Jan; 31(1):99-107. PubMed ID: 19243710
[TBL] [Abstract][Full Text] [Related]
10. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms.
Lanier BQ; Gross RD; Marks BB; Cockrum PC; Juniper EF
Ann Allergy Asthma Immunol; 2001 Jun; 86(6):641-8. PubMed ID: 11428736
[TBL] [Abstract][Full Text] [Related]
11. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
Leonardi A; Quintieri L
Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
Avunduk AM; Tekelioglu Y; Turk A; Akyol N
Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
[TBL] [Abstract][Full Text] [Related]
13. A review of olopatadine for the treatment of ocular allergy.
Abelson MB
Expert Opin Pharmacother; 2004 Sep; 5(9):1979-94. PubMed ID: 15330735
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.
Ohmori K; Hayashi K; Kaise T; Ohshima E; Kobayashi S; Yamazaki T; Mukouyama A
Jpn J Pharmacol; 2002 Apr; 88(4):379-97. PubMed ID: 12046981
[TBL] [Abstract][Full Text] [Related]
15. The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation.
Pipkorn P; Costantini C; Reynolds C; Wall M; Drake M; Sanico A; Proud D; Togias A
Ann Allergy Asthma Immunol; 2008 Jul; 101(1):82-9. PubMed ID: 18681089
[TBL] [Abstract][Full Text] [Related]
16. Evolving paradigm in the management of allergic rhinitis-associated ocular symptoms: role of intranasal corticosteroids.
Blaiss MS
Curr Med Res Opin; 2008 Mar; 24(3):821-36. PubMed ID: 18257976
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
Vogelson CT; Abelson MB; Pasquine T; Stephens DM; Gamache DA; Gross RD; Robertson SM; Yanni JM
Allergy Asthma Proc; 2004; 25(1):69-75. PubMed ID: 15055565
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis.
Meltzer EO; Hampel FC; Ratner PH; Bernstein DI; Larsen LV; Berger WE; Finn AF; Marple BF; Roland PS; Wall GM; Brubaker MJ; Dimas C; Potts SL; Silver LH; Barnes JR
Ann Allergy Asthma Immunol; 2005 Dec; 95(6):600-6. PubMed ID: 16400902
[TBL] [Abstract][Full Text] [Related]
19. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis.
Ono SJ; Lane K
Drug Des Devel Ther; 2011 Feb; 5():77-84. PubMed ID: 21340041
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
